In keeping with such empirical practice, rechallenge with anti-EGFR agents is deployed according to the described decay of resistance mechanisms11, its manageable toxicity profile and potential induction of tumor shrinkage20,22,23. This evidence concerns the gene EGFR and neoplasm.